Catalina Lopez-Correa
Technik-/Wissenschafts-/F&E-Leiter bei Algae-C, Inc.
Profil
Catalina Lopez-Correa is currently the Director, Head-Genomics, Research & Development at Algae-C, Inc. Previously, she worked as the Chief Scientific Officer & VP-Sector Development at Genome British Columbia from 2016 to 2019 and as the Chief Scientific Officer & VP-Scientific at Génome Québec, Inc. She holds a doctorate degree from Katholieke Universiteit Leuven and Pontifical Bolivarian University.
Aktive Positionen von Catalina Lopez-Correa
Unternehmen | Position | Beginn |
---|---|---|
Algae-C, Inc.
Algae-C, Inc. BiotechnologyHealth Technology Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ehemalige bekannte Positionen von Catalina Lopez-Correa
Unternehmen | Position | Ende |
---|---|---|
Genome British Columbia
Genome British Columbia Miscellaneous Commercial ServicesCommercial Services Genome British Columbia invests in and manages genomics and proteomics research projects. It offers services in human health, environment, agriculture, forestry, mining, energy, aquaculture, and fisheries. The company was founded in 2000 and is headquartered in Vancouver, Canada. | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2019 |
Génome Québec, Inc.
Génome Québec, Inc. Miscellaneous Commercial ServicesCommercial Services Génome Québec, Inc. develops genomics and DNA in Quebec. It helps to accelerate the discovery of new applications for genomics and DNA in strategic areas such as human health, forestry and the environment. The company was founded in 2000 and is headquartered in Montreal, Canada. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Catalina Lopez-Correa
Pontifical Bolivarian University | Doctorate Degree |
Katholieke Universiteit Leuven | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Génome Québec, Inc.
Génome Québec, Inc. Miscellaneous Commercial ServicesCommercial Services Génome Québec, Inc. develops genomics and DNA in Quebec. It helps to accelerate the discovery of new applications for genomics and DNA in strategic areas such as human health, forestry and the environment. The company was founded in 2000 and is headquartered in Montreal, Canada. | Commercial Services |
Genome British Columbia
Genome British Columbia Miscellaneous Commercial ServicesCommercial Services Genome British Columbia invests in and manages genomics and proteomics research projects. It offers services in human health, environment, agriculture, forestry, mining, energy, aquaculture, and fisheries. The company was founded in 2000 and is headquartered in Vancouver, Canada. | Commercial Services |
Algae-C, Inc.
Algae-C, Inc. BiotechnologyHealth Technology Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then. | Health Technology |